Interview: Ed Dybka – President and CEO, AstraZeneca Canada
Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed…
AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.
The company employs more than 700 people in Canada who work to research, develop and market innovative medicines. AstraZeneca Canada was recently designated a global Clinical Hub for oncology and immuno-oncology clinical studies. We are currently leading global oncology clinical studies in lung, head and neck cancer.
We are focused on developing innovative medicines in three core areas: Cardiovascular and Metabolic diseases (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA).
In 2015, AstraZeneca invested more than $54 million in Canadian health sciences research in our focus areas.
Contact
1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada
Tel (+1) 905 277-7111
Website https://www.astrazeneca.ca/en
Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed…
For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward…
In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
Rare diseases remain among the most complex and least visible challenges facing healthcare systems, particularly in regions where genetic factors amplify the burden. In this conversation, Ahmed Salem, Head of…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
Alexandre Gibim, senior Vice President of Latin America at AstraZeneca, brings extensive global pharmaceutical leadership experience spanning China, the US, and Canada. In this exclusive interview, he articulates AstraZeneca’s strategic…
After two decades with AstraZeneca across Europe and the United States, Anne-Laure Dreno now leads the group’s French affiliate at a time of exceptional scientific and organisational momentum. In this…
The latest updates from the US healthcare and life sciences scene. Eli Lilly partners with Nvidia to build a supercomputer for faster drug discovery; Trump secures “most-favored-nation” pricing deals with…
See our Cookie Privacy Policy Here
